Adimab Reports Strong Partnering Year for 2025
23 Overall Partnerships in 2025 – – 75 New Programs Added in 2025 – – 50 Milestones Achieved in 2025 – – Generated More Than 650 Total Therapeutic Programs to Date – Adimab, LLC, the global leader in the discovery and engineering of fully human monoclonal and multispecific antibodies, today announced that it entered into […]